Evidence for Ethylene-Vinyl-Alcohol-Copolymer Liquid Embolic Agent as a Monotherapy in Treatment of Endoleaks

Jamieson, Russell W.; Bachoo, Paul; Tambyraja, Andrew L.

doi:10.1016/j.ejvs.2016.02.015

Cited by 22 publications

(22 citation statements)

References 20 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current literature is deficient regarding this agent's long-term durability in the treatment of T2ELs and therefore, we sought to evaluate our results of using Onyx to treat T2ELs following EVAR. 14…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (Onyx^TM)

Nuckles

Nadal

Berger

et al. 2020

Vasc Endovascular Surg

View full text Add to dashboard Cite

Introduction: This study reports our experience with the use of an ethylene vinyl alcohol copolymer (Onyx™) for the treatment of type II endoleak after endovascular repair of abdominal aortic aneurysms (EVAR) in comparison to coils and cyanoacrylate glue. Methods: Clinical data of all patients treated for type II endoleak following EVAR between 2009 and 2017 were retrospectively analyzed. Abdominal aortic aneurysm (AAA) diameter and AAA sac volume during follow-up were measured using computed tomography angiography (CTA). Treatment failure variables were created for the change in sac diameter and volume. An increase in sac diameter ≥ 5 mm was considered a failure, as was an increase ≥ 10% in AAA sac volume. Results: 35 patients underwent treatment for a persistent type II endoleak following EVAR. Of these patients, 18 (51.4%) were treated with Onyx and 17 (48.6%) were treated with coils ± cyanoacrylate glue embolization. There were no significant differences between the 2 groups with regard to demographics. The average volume of Onyx used per treatment was 13.4 ml (range 4.5 ml- 39 ml). There was no difference in efficacy between the Onyx and non-Onyx group. Complications were limited to 1 non-target embolization without significant clinical sequelae. Conclusions: Ethylene vinyl alcohol copolymer (Onyx™) embolization is similarly effective compared to traditional cyanoacrylate glue or coil embolization in the treatment of type II endoleak after EVAR.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (Onyx^TM)

Nuckles

Nadal

Berger

et al. 2020

Vasc Endovascular Surg

View full text Add to dashboard Cite

show abstract

“…Access to the Type II endoleak can be achieved with a trans-lumbar or trans-caval aortic puncture, and aortic sac embolization can be achieved with the use of metallic coils or polymers [ 6 ]. Polymer-based embolization can be achieved with either Ethylene-Vinyl-Copolymer (Onyx TM ) liquid or NBCA [ 8 , 9 ]. In this patient, a standard trans-lumbar direct aortic sac puncture was performed, and glue was used to achieve sac embolization while reducing the risk of embolic reflux into the feeding lumbar arteries.…”

Section: Discussionmentioning

confidence: 99%

Trans-luminal repair of a ruptured AAA with Type Ia and Type II endoleaks

Kuziez

Picus

Sánchez

et al. 2018

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Ruptured abdominal aortic aneurysm (rAAA) with an associated Type II endoleak is rare. Emergent surgical repair is often necessary and may be associated with high morbidity and mortality. We report an alternative unique trans-luminal repair strategy in an 84-year-old male who presented with a rAAA with prior EVAR, and Type Ia and Type II endoleaks. The operative strategy consisted of proximal endograft extension into the para-renal aorta, followed by staged sac embolization using glue. Postoperatively, the patient recovered well from the repair, and follow-up imaging demonstrated a stable repair.

show abstract

“…The occlusion obtained is permanent. EVOH has been found effective and safe for treating cerebral arteriovenous malformations, type II endoleaks, hemoptysis, renal angiomyolipomas, and for peripheral hemostasis (11)(12)(13)(14)(15)(16)(17). When used for PVE, EVOH seemed to result in faster growth of FLR compared to other embolic agents (18).…”

Section: Original Articlementioning

confidence: 99%

Portal vein embolization with ethylene-vinyl alcohol copolymer for contralateral lobe hypertrophy before liver resection: safety, feasibility and initial experience

Gautier¹,

Chevallier²,

Mastier³

et al. 2021

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background: To report our preliminary experience with preoperative portal vein embolization (PVE) using liquid ethylene vinyl alcohol (EVOH) copolymer.Methods: Retrospectively review of patients with primary or secondary liver malignancies scheduled for extensive hepatectomy after the induction of future liver remnant (FLR) hypertrophy by right or left PVE with EVOH as the only embolic agent between 2014 and 2018 at two academic centers. Cross-sectional imaging liver volumetry data obtained before and 3-6 weeks after PVE were used to assess the FLR volume (FLRV) increase, degree of FLR hypertrophy and the FLR kinetic growth rate (KGR).Results: Twenty-six patients (17 males; mean age, 58.7±11 years; range, 32-79 years) were included. The technical and clinical success rate was 100%. PVE produced adequate FLR hypertrophy in all patients.Embolization occurred in all targeted portal branches and in no non-target vessels. The %FLRV increased by 52.9%±32.5% and the degree of FLR hypertrophy was 16.7%±6.8%. The KGR was 4.4%±2.0% per week. Four patients experience minor complications after PVE which resolved with symptomatic treatment.The resection rate was 84.5%. One patient died during surgery for reasons unrelated to PVE.

show abstract

Evidence for Ethylene-Vinyl-Alcohol-Copolymer Liquid Embolic Agent as a Monotherapy in Treatment of Endoleaks

Cited by 22 publications

References 20 publications

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (Onyx^TM)

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (Onyx^TM)

Trans-luminal repair of a ruptured AAA with Type Ia and Type II endoleaks

Portal vein embolization with ethylene-vinyl alcohol copolymer for contralateral lobe hypertrophy before liver resection: safety, feasibility and initial experience

Contact Info

Product

Resources

About

Evidence for Ethylene-Vinyl-Alcohol-Copolymer Liquid Embolic Agent as a Monotherapy in Treatment of Endoleaks

Cited by 22 publications

References 20 publications

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (OnyxTM)

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (OnyxTM)

Trans-luminal repair of a ruptured AAA with Type Ia and Type II endoleaks

Portal vein embolization with ethylene-vinyl alcohol copolymer for contralateral lobe hypertrophy before liver resection: safety, feasibility and initial experience

Contact Info

Product

Resources

About

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (Onyx^TM)

Outcomes of Type II Endoleak Treatment Using Ethylene Vinyl Alcohol Copolymer (Onyx^TM)